Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0234)
| Name |
Gastrodin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Gastrodin; 62499-27-8; Gastrodine; Gastrodin Hemihydrate; UNII-5YS9U2W3RQ; 5YS9U2W3RQ; 4-(Hydroxymethyl)phenyl beta-D-Glucopyranoside; beta-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (-)-GASTRODIN; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(hydroxymethyl)phenoxy]oxane-3,4,5-triol; CHEMBL274739; CHEBI:80828; 4-(Hydroxymethyl)phenyl-beta-D-glucopyranoside; Gastrodin,(S); Gastrodin (Gastrodine); GASTRODIN [MI]; 4-(beta-D-glucopyranosyloxy)benzyl alcohol; GASTRODIN [INCI]; 2H-pyran-3,4,5-triol; GASTRODIN [WHO-DD]; SCHEMBL1076037; Gastrodin, >=98% (HPLC); DTXSID30978086; HMS3884L15; HY-N0115; BDBM50177403; MFCD00272169; s2383; (4-(hydroxymethyl)phenoxy)tetrahydro-; AKOS015951256; 4-; A-D-Glucopyranosyloxybenzyl alcohol; AC-8028; BCP9000710; CCG-267336; CS-7969; NCGC00346601-02; AS-17473; Gastrodin, from Gastrodia alata, >=98%; 4-[beta-d-glucopyranosyloxy] benzyl alcohol; 4-(beta-D-GLUCOPYRANOSYL)-BENZYLALCOHOL; 4-(Hydroxymethyl)phenylbeta-D-Glucopyranoside; b-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-; C16964; 4-(.BETA.-D-GLUCOPYRANOSYL)-BENZYLALCOHOL; A833810; Q-100720; Q5526833; 4-(.BETA.-D-GLUCOPYRANOSYLOXY)BENZYL ALCOHOL; beta-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL-; .BETA.-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL; .BETA.-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL-; 4-HYDROXYBENZYL ALCOHOL 4-O-beta-D-GLUCOPYRANOSIDE; 4-HYDROXYBENZYL ALCOHOL 4-O-.BETA.-D-GLUCOPYRANOSIDE; NCGC00346601-02_C13H18O7_beta-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(hydroxymethyl)phenoxy)-tetrahydro-2H-pyran-3,4,5-triol
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C13H18O7
|
||||
| IUPAC Name |
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
|
||||
| Canonical SMILES |
C1=CC(=CC=C1CO)OC2C(C(C(C(O2)CO)O)O)O
|
||||
| InChI |
InChI=1S/C13H18O7/c14-5-7-1-3-8(4-2-7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1
|
||||
| InChIKey |
PUQSUZTXKPLAPR-UJPOAAIJSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 3 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Vascular dementia | ICD-11: 6D81 | |||
| Responsed Regulator | Kelch-like ECH-associated protein 1 (KEAP1) | Driver | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 | |
| In Vivo Model |
Male Sprague-Dawley rats (weight 260 ± 20 g; Guizhou Medical University Experimental Animal Center; Certificate No. SCXK2018-0001; Grant No. 2200483) were reared in a specific pathogen-free environment with 12 h light/dark cycle and 55% ± 10% humidity at a temperature of 20~25 , were provided with sufficient feed and sterile drinking water and fasted for 6 h before and after surgery. All animal experiments were performed in accordance with the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals.
Click to Show/Hide
|
||||
| Response regulation | Gastrodin (GAS) inhibited ferroptosis in hippocampal neurons by activating the Nrf2/ Keap1-GPx4 signaling pathway, suggesting its possible application as a functional food for improving vascular dementia by inhibiting ferroptosis. | ||||
| Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [2] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Parkinson disease | ICD-11: 8A00 | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | C6 cells | Malignant glioma | Rattus norvegicus | CVCL_0194 | |
| Response regulation | Gastrodin induced GPX4, Nrf2 and HO-1 expression to protect C6 cells from H2O2-induced ferroptosis. Gastrodin pretreatment effectively reduced H2O2-induced oxidative damage, indicating gastrodin is a potential antioxidant that reduced cytotoxic ROS. The role of gastrodin in ferroptosis presents a new perspective for understanding parkinson's disease. | ||||
| Experiment 3 Reporting the Ferroptosis-centered Drug Act on This Target | [3] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Nervous system disease | ICD-11: 8E7Z | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 | |
| Response regulation | Gastrodin (GAS) is a component of Gastrodia elata Blume, with strong antioxidant activity in neurodegenerative diseases. GAS increased the nuclear translocation of Nrf2, up-regulated the downstream HO-1 protein expression in HT-22 cells following treatment with glutamate. | ||||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Vascular dementia | ICD-11: 6D81 | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 | |
| In Vivo Model |
Male Sprague-Dawley rats (weight 260 ± 20 g; Guizhou Medical University Experimental Animal Center; Certificate No. SCXK2018-0001; Grant No. 2200483) were reared in a specific pathogen-free environment with 12 h light/dark cycle and 55% ± 10% humidity at a temperature of 20~25 , were provided with sufficient feed and sterile drinking water and fasted for 6 h before and after surgery. All animal experiments were performed in accordance with the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals.
Click to Show/Hide
|
||||
| Response regulation | Gastrodin (GAS) inhibited ferroptosis in hippocampal neurons by activating the Nrf2/Keap1-GPx4 signaling pathway, suggesting its possible application as a functional food for improving vascular dementia by inhibiting ferroptosis. | ||||
Heme oxygenase 1 (HMOX1)
| In total 2 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [2] | |||
| Target for Ferroptosis | Driver/Suppressor | |||
| Responsed Disease | Parkinson disease | ICD-11: 8A00 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | C6 cells | Malignant glioma | Rattus norvegicus | CVCL_0194 |
| Response regulation | Gastrodin induced GPX4, Nrf2 and HO-1 expression to protect C6 cells from H2O2-induced ferroptosis. Gastrodin pretreatment effectively reduced H2O2-induced oxidative damage, indicating gastrodin is a potential antioxidant that reduced cytotoxic ROS. The role of gastrodin in ferroptosis presents a new perspective for understanding parkinson's disease. | |||
| Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [3] | |||
| Target for Ferroptosis | Driver/Suppressor | |||
| Responsed Disease | Nervous system disease | ICD-11: 8E7Z | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 |
| Response regulation | Gastrodin (GAS) is a component of Gastrodia elata Blume, with strong antioxidant activity in neurodegenerative diseases. GAS increased the nuclear translocation of Nrf2, up-regulated the downstream HO-1 protein expression in HT-22 cells following treatment with glutamate. | |||
References